![The F-35’s future: Can the fifth-gen fighter withstand political, technological headwinds? [Video]](https://breakingdefense.com/wp-content/uploads/sites/3/2024/04/240401_f35_clouds_8270083-scaled-e1711999276822.jpg?#)
Chasing Sarepta, RegenXBio links DMD gene therapy to improved outcomes
RegenXBio has shared updated phase 1/2 data on its Duchenne muscular dystrophy (DMD) gene therapy, providing evidence that its pivotal dose improves functional outcomes in older boys with the disease.
RegenXBio has shared updated phase 1/2 data on its Duchenne muscular dystrophy (DMD) gene therapy, providing evidence that its pivotal dose improves functional outcomes in older boys with the disease.
